Article

Hydrocodone Combos Go Schedule II on Oct. 6: What To Do

Painkillers containing hydrocodone will have more restricted prescribing procedures in a few days. Briefly, here's the mandated change in procedures.

In three days, on October 6, a new rule from the Drug Enforcement Administration (DEA) reclassifies hydrocodone-containing  combination painkillers as Schedule II controlled substances. Prescribing procedures for these medications must change, and are more restricted.

If you act very quickly, there's a six-month exception useful for patients who are in remote areas or otherwise challenged by getting refills: "Any prescriptions ... that are issued before October 6, 2014, and authorized for refilling, may be dispensed ... if such dispensing occurs before April 8, 2015." (See the second-last page in the rule published in the Federal Register.)

The American Medical Association has published a handy list of steps you will need to take after October 6 to prescribe these medications, as well as a printout for patients.

In brief, you now need to:

 --   Issue new prescriptions. Refills are no longer allowed, and the limit is a 90-day supply.
 --   Hand-write prescriptions (unless you and the pharmacy are certified for eScripts). Except for closely regulated emergency procedures, phoned or faxed prescriptions for these painkillers can't be filled.
 --  Allied health professionals may not be able to prescribe these drugs, depending on the state where they work

 

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.